Virtual Library
Start Your Search
V.A. Alvarenga
Author of
-
+
P3.02c - Poster Session with Presenters Present (ID 472)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02c-009 - Anti-VEGF and Anti-EGFR Reduce Malignant Pleural Effusion and Morbidity in an Experimental Adenocarcinoma Model (ID 5501)
14:30 - 14:30 | Author(s): V.A. Alvarenga
- Abstract
Background:
Lung cancer is a main cause of death by cancer worldwide and adenocarcinoma the most common cell type. Most of patients present pleural effusion at an advanced stage of the disease with high morbidity and mortality, however its pathogenesis is still poorly understood and therapeutic options are limited. OBJECTIVE: Evaluate the effects of intrapleural anti-VEGF and anti-EGFR in malignant pleural effusion induced in an experimental model.
Methods:
One hundred and twenty C57BL/6 mice received intrapleural injection of 0.5x10[5] of LLC cells and were divided into four groups that received, after 3, 7, 10 and 14 days, anti-VEGF, anti-EGFR, anti-VEGF+anti-EGFR or PBS (control) intrapleurally. Ten animals for each group were followed until death to evaluate the survival curve. Eighty animals were euthanized after 7, 10, 14 or 21 days after LLC injection and had weight (g), mobility (score 0-3), pleural fluid volume evaluated. Presence of tumor in pleura and pericardium, inflammatory cells in lung parenchyma, histological changes in kidney, liver and spleen and tumor apoptosis (TUNEL) and proliferation (PCNA) were evaluated by score (0-4). Statistical analysis: One Way ANOVA, Kaplan–Meier curve, p<0.05.
Results:
In the survival analysis, pleural carcinomatosis was lethal showed maximum survival of 25 days without statistical differences among groups (p=0.739). Reduction of body weight mice was observed in all groups after 21 days (p<0.05). However, the animals mobility was better in the groups that received anti-EGFR (p=0.026). The fluid volume was higher in all control groups no matter the study time (p=0.010). Tumor implants in the pleura were more evident in control groups compared to treated groups after 14 days (p=0.001). Neoplastic infiltration of lung parenchyma was observed only in a few animals. However, lung parenchymal inflammation was minimal in all groups. Histological evaluation of pericardium and heart muscle showed tumor implants mainly in the 21-day in the control group. In liver and kidney steatosis were observed after 14 days in control group (p<0.001). Hyperplasia of the white pulp of the spleen was observed at all evaluation time points with greater evidence at 21-day in the control group (p<0.001). High scores of apoptosis and lower scores of tumor proliferation were observed in the groups that received treatment with anti-EGFR and anti-VEGF+antiEGFR.
Conclusion:
In this experimental model, the target therapies reduced significantly the pleural fluid volume, morbidity and histological parameters mainly in the therapies with EGFR, although its action did not increased the survival of the animals.
